NCT06041516View on ClinicalTrials.gov

Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 17, 2024

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2029

Conditions
Neuroendocrine CarcinomasNeuroendocrine TumorsCarcinoma, NeuroendocrineCarcinoma, AdrenocorticalCarcinoma, Adrenal Cortical
Interventions
DRUG

ADCT-701

ADCT-701 in 2microgram/kg-255microgram/kg (weight based dosing), IV over 30 minutes (+15 minutes)

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT06041516 - Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas | Biotech Hunter | Biotech Hunter